IS6329A - Lyf til að meðhöndla illkynja æxli - Google Patents
Lyf til að meðhöndla illkynja æxliInfo
- Publication number
- IS6329A IS6329A IS6329A IS6329A IS6329A IS 6329 A IS6329 A IS 6329A IS 6329 A IS6329 A IS 6329A IS 6329 A IS6329 A IS 6329A IS 6329 A IS6329 A IS 6329A
- Authority
- IS
- Iceland
- Prior art keywords
- drugs
- malignant tumors
- treat malignant
- compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Quinoline Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16140799P | 1999-10-25 | 1999-10-25 | |
SE9903838A SE9903838D0 (sv) | 1999-10-25 | 1999-10-25 | Novel compounds |
US21281600P | 2000-06-21 | 2000-06-21 | |
SE0002320A SE0002320D0 (sv) | 1999-10-25 | 2000-06-21 | Malignant tumors |
PCT/SE2000/002055 WO2001030758A1 (en) | 1999-10-25 | 2000-10-24 | Drugs for the treatment of malignant tumours |
Publications (2)
Publication Number | Publication Date |
---|---|
IS6329A true IS6329A (is) | 2002-04-02 |
IS2750B IS2750B (is) | 2011-08-15 |
Family
ID=27484521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IS6329A IS2750B (is) | 1999-10-25 | 2002-04-02 | Leiðarafesting |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1224172B1 (is) |
JP (1) | JP3950337B2 (is) |
KR (2) | KR100674160B1 (is) |
AT (1) | ATE358668T1 (is) |
AU (1) | AU775057B2 (is) |
CA (1) | CA2386775C (is) |
CZ (1) | CZ298534B6 (is) |
DE (1) | DE60034240T2 (is) |
DK (1) | DK1224172T3 (is) |
EE (1) | EE200200207A (is) |
ES (1) | ES2280258T3 (is) |
HK (1) | HK1049830A1 (is) |
HR (1) | HRP20020353A2 (is) |
HU (1) | HU229072B1 (is) |
IL (2) | IL148782A0 (is) |
IS (1) | IS2750B (is) |
NO (1) | NO323320B1 (is) |
NZ (1) | NZ518296A (is) |
SE (1) | SE0002320D0 (is) |
UA (1) | UA73748C2 (is) |
WO (1) | WO2001030758A1 (is) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
US8314124B2 (en) | 2004-02-06 | 2012-11-20 | Active Biotech Ab | Crystalline salts of quinoline compounds and methods for preparing them |
SE0400235D0 (sv) * | 2004-02-06 | 2004-02-06 | Active Biotech Ab | New composition containing quinoline compounds |
SE0401578D0 (sv) * | 2004-06-18 | 2004-06-18 | Active Biotech Ab | Novel compounds |
NZ587551A (en) | 2004-06-24 | 2012-01-12 | Vertex Pharma | 5-Amino-phenol derivatives such as 5-amino-2,4-di-tert-butyl-phenol |
US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
EP1937642B1 (en) | 2005-10-19 | 2014-09-10 | Teva Pharmaceutical Industries Ltd | Crystals of laquinimod sodium, and process for the manufacture thereof |
SI3219705T1 (sl) | 2005-12-28 | 2020-08-31 | Vertex Pharmaceuticals Incorporated | Farmacevtski sestavki amorfne oblike N-(2,4-bis(1,1-dimetiletil)-5- hidroksifenil)-1,4-dihidro-4-oksokinolin-3-karboksamid |
WO2007146248A2 (en) | 2006-06-12 | 2007-12-21 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
KR100916160B1 (ko) * | 2007-02-21 | 2009-09-08 | (주)바이오버드 | 약제학적 항암 조성물 |
EP2065380A1 (en) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Pyridoneamide derivatives as focal adhesion kinase (FAK) inhibitors and their use for the treatment of cancer |
ES2600920T3 (es) | 2007-12-20 | 2017-02-13 | Teva Pharmaceutical Industries, Ltd. | Preparaciones estables de laquinimod |
AU2009288108B2 (en) | 2008-09-03 | 2013-10-17 | Teva Pharmaceutical Industries, Ltd. | 2-oxo-1,2-dihydro-quinoline modulators of immune function |
RU2543714C2 (ru) | 2009-03-20 | 2015-03-10 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения модуляторов регулятора трансмембранной проводимости кистозного фиброза |
CA2813711A1 (en) * | 2010-10-14 | 2012-04-19 | Immunahr Ab | 1,2-dihydro-4-hydroxy-2-oxo-quinoline-3-carboxanilides as ahr activators. |
US8802700B2 (en) | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
EP2537517A1 (en) * | 2011-06-22 | 2012-12-26 | Active Biotech AB | Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide |
BR112014021090B1 (pt) | 2012-02-27 | 2023-01-24 | Vertex Pharmaceuticals Incorporated | Composição farmacêutica e uso de n-[2,4-bis(1,1-dimetiletil)-5-hidróxifenil]-1,4-di-hidro-4-oxoquinolina3-carboxamida na preparação da mesma |
EP2916915A4 (en) * | 2012-11-07 | 2016-06-22 | Teva Pharma | LAQUINIMOD AMINE SALTS |
MX2015011627A (es) | 2013-03-14 | 2016-05-16 | Teva Pharma | Cristales de laquinimod sodico y proceso mejorado para la elaboracion de los mismos. |
EP3041472B1 (en) | 2014-09-23 | 2017-02-01 | Active Biotech AB | Quinoline carboxamides for use in the treatment of multiple myeloma |
RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
CA2967112C (en) | 2014-11-19 | 2023-05-16 | Active Biotech Ab | Quinoline carboxamides for use in the treatment of leukemia |
WO2019074116A1 (ja) | 2017-10-13 | 2019-04-18 | 小野薬品工業株式会社 | Axl阻害剤を有効成分として含む固形がん治療剤 |
CN115209881A (zh) | 2020-03-03 | 2022-10-18 | 活跃生物技术有限公司 | 用于组合疗法的他喹莫德或其药学上可接受的盐 |
BR112022023448A2 (pt) * | 2020-05-21 | 2023-01-31 | Stemsynergy Therapeutics Inc | Inibidores de notch e usos dos mesmos |
WO2022152902A1 (en) | 2021-01-18 | 2022-07-21 | Active Biotech Ab | Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome |
EP4346773A1 (en) | 2021-05-25 | 2024-04-10 | Active Biotech AB | A plurality of tasquinimod particles and use thereof |
EP4363404A1 (en) | 2021-07-02 | 2024-05-08 | Active Biotech AB | A pharmaceutical product containing tasquinimod and a method for assessing the purity of said product |
TWI838849B (zh) * | 2021-09-13 | 2024-04-11 | 美商美國禮來大藥廠 | Ahr促效劑 |
AR126963A1 (es) | 2021-09-13 | 2023-12-06 | Lilly Co Eli | Agonistas de ahr |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE52670B1 (en) * | 1981-03-03 | 1988-01-20 | Leo Ab | Heterocyclic carboxamides,compositions containing such compounds,and processes for their preparation |
GB9108547D0 (en) * | 1991-04-22 | 1991-06-05 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB9404378D0 (en) * | 1994-03-07 | 1994-04-20 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
GB2290786A (en) * | 1994-06-30 | 1996-01-10 | Fujisawa Pharmaceutical Co | Quinoline derivatives |
SE9801474D0 (sv) * | 1998-04-27 | 1998-04-27 | Active Biotech Ab | Quinoline Derivatives |
SE9802550D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
US6121287A (en) * | 1998-07-15 | 2000-09-19 | Active Biotech Ab | Quinoline derivatives |
SE9802549D0 (sv) * | 1998-07-15 | 1998-07-15 | Active Biotech Ab | Quinoline derivatives |
-
2000
- 2000-06-21 SE SE0002320A patent/SE0002320D0/xx unknown
- 2000-10-24 KR KR1020067008739A patent/KR100674160B1/ko not_active IP Right Cessation
- 2000-10-24 WO PCT/SE2000/002055 patent/WO2001030758A1/en active IP Right Grant
- 2000-10-24 KR KR1020027005077A patent/KR100597938B1/ko not_active IP Right Cessation
- 2000-10-24 UA UA2002032524A patent/UA73748C2/uk unknown
- 2000-10-24 DE DE60034240T patent/DE60034240T2/de not_active Expired - Lifetime
- 2000-10-24 HU HU0203238A patent/HU229072B1/hu not_active IP Right Cessation
- 2000-10-24 DK DK00973329T patent/DK1224172T3/da active
- 2000-10-24 JP JP2001533112A patent/JP3950337B2/ja not_active Expired - Fee Related
- 2000-10-24 ES ES00973329T patent/ES2280258T3/es not_active Expired - Lifetime
- 2000-10-24 EP EP00973329A patent/EP1224172B1/en not_active Expired - Lifetime
- 2000-10-24 AU AU11851/01A patent/AU775057B2/en not_active Ceased
- 2000-10-24 IL IL14878200A patent/IL148782A0/xx active IP Right Grant
- 2000-10-24 EE EEP200200207A patent/EE200200207A/xx unknown
- 2000-10-24 CZ CZ20021293A patent/CZ298534B6/cs not_active IP Right Cessation
- 2000-10-24 CA CA002386775A patent/CA2386775C/en not_active Expired - Fee Related
- 2000-10-24 NZ NZ518296A patent/NZ518296A/xx not_active IP Right Cessation
- 2000-10-24 AT AT00973329T patent/ATE358668T1/de not_active IP Right Cessation
-
2002
- 2002-03-20 IL IL148782A patent/IL148782A/en not_active IP Right Cessation
- 2002-04-02 IS IS6329A patent/IS2750B/is unknown
- 2002-04-23 HR HR20020353A patent/HRP20020353A2/hr not_active Application Discontinuation
- 2002-04-24 NO NO20021932A patent/NO323320B1/no not_active IP Right Cessation
-
2003
- 2003-01-24 HK HK03100644.7A patent/HK1049830A1/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IS6329A (is) | Lyf til að meðhöndla illkynja æxli | |
YU23202A (sh) | Lekovi za tretman malignih tumora | |
DK1519724T3 (da) | Fredericamycin-derivater som lægemidler til behandling af tumorer | |
BR0112589A (pt) | Derivados de heteroarila e sua aplicação como medicamento | |
DE60030741D1 (de) | Chinazoline verbindungen als heilmittel | |
RU2011138835A (ru) | Применение производного рапамицина | |
SE9904505D0 (sv) | Novel compounds | |
PL367682A1 (en) | Dolastatin 10 derivatives | |
BR0309355A (pt) | 2-(2,6-diclorofenil)-diarilimidazóis | |
CY1109681T1 (el) | Υποκατεστημενα παραγωγα κιναζολινης ως αναστολεις των κινασων aurora | |
BR0209431A (pt) | Novos compostos de 4-anilinoquinolino-3-carboxamidas | |
NO20024005D0 (no) | Pteridinforbindelser for behandling av psoriasis | |
GB0112348D0 (en) | Compounds | |
ATE233754T1 (de) | Diphenyl-piperidin derivate | |
ATE405568T1 (de) | Cytotoxische mittel | |
ATE238981T1 (de) | Antitumorwirkstoffe | |
BR0112807A (pt) | Derivados de indol e sua aplicação como medicamento | |
HUP0105281A2 (hu) | Rákellenes hatású benzaldehidszármazékok és gyógyászati alkalmazásuk | |
TW200634002A (en) | Chemical compounds | |
DE60123117D1 (de) | Verwendung von alpha-halogenacryloyl-distamycin derivaten zur herstellung eines medikaments zur behandlung von krebs | |
MXPA04005809A (es) | Inhibidores de proteinas quinasas. | |
CY1106576T1 (el) | Υποκατεστημενα παραγωγα 2-πυρρολιδιν-2-υλ-1h-ινδολης για τη θεραπεια ημικρανιας | |
NO20030420L (no) | Medikament for immunoterapi av maligne tumorer | |
SE0004827D0 (sv) | Therapeutic compounds | |
TW200505913A (en) | Novel oxazole derivatives, their manufacture and use as pharmaceutical agents |